JYJehan Ahmed Younis

Jehan Ahmed Younis

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Jehan Ahmed Younis has a total of 10 co-authors. Here are the top co-authors by number of shared publications:

  • Hosna Moustafa

    Oncology and Nuclear Medicine Department, Kasr Al-Aini Hospital, Cairo University, Egypt

    2 shared publications
  • Ayman Ismail Kamel

    Faculty of Medicine, Cairo University, Giza, Eygpt

    1 shared publication
  • Eman Mohammed Zaki

    Department of Radiology, National Cancer Institute, Children Cancer Hospital, Cairo, Egypt

    1 shared publication
  • Hala Taha Salem

    Department of Pathology, National Cancer Institute, Children Cancer Hospital, Cairo, Egypt

    1 shared publication
  • Ismael Mohammed Al Antably

    Department of Nuclear Medicine, National Cancer Institute, Children Cancer Hospital, Cairo, Egypt

    1 shared publication
  • Khalid Taalab

    Nuclear Medicine Consultant in El-Galaa Hospital & Maadi Armed Forced Hospital

    1 shared publication

Latest Publications

  • Open Access

    Role of 18F-fluorodeoxyglucose positron emission tomography/computed tomography and magnetic resonance imaging in prediction of response to neoadjuvant chemotherapy in pediatric osteosarcoma

    by Jehan Ahmed Younis, Ismael Mohammed Al Antably, Manal Zamzam, Hala Taha Salem, Eman Mohammed Zaki, Omneya Ahmed Hassanian

    The aim of our study was to evaluate the role of18F-fluorodeoxyglucose positron emission tomography/computed tomography (PET/CT) and magnetic resonance imaging (MRI) in prediction of response to neoadjuvant chemotherapy (NAC) in pediatric osteosarcoma (OS) patients compared to percentage of tumor necrosis after surgical excision of the tumor. Forty-six pediatric OS patients treated with neoadjuvant chemotherapy and surgery were underwent PET/CT and MRI before, after 3 cycles, and after the completion of neoadjuvant chemotherapy. Imaging parameters include maximum standardized uptake value (SUVmax1, 2, and 3), tumor liver ratio (TLR 1, 2, and 3), and MRI tumor volume (MRTV 1, 2, and 3) at initial assessment before starting NAC, after finishing three cycles and after finishing 6 cycles before tumor excision, respectively. Cutoff values of the PET/CT and MRI parameters were determined using receiver operating characteristic (ROC) curve analysis and percentage of tumor necrosis of postsurgical specimen. Fourteen patients were good responders (30.4%), with more than 90% tumor necrosis, while 31 patients were poor responders (67.4%). The results of one patient were missed. We noticed that higher sensitivity for detecting poor responders was detected by SUVmax3/1, TLR3/1, and MRTV2/1 ratio cutoff values, while higher specificity was detected by TRL2 and SUVmax3 cutoff values. ROC curve analysis of MRTV2/1 and MRTV3/1 ratio was fair in predicting poor responders. PET/CT parameters are capable of predicting histological response to NAC in OS patients with overall sensitivity and specificity higher than MRI parameters.


  • Open Access

    Additive value of 99mTechnetium methylene diphosphonate hybrid single-photon emission computed tomography/computed tomography in the diagnosis of skull base osteomyelitis in otitis externa patients compared to planar bone scintigraphy

    by Jehan Ahmed Younis

    The aim of this study was to evaluate the additive value of 99mtechnetium methylene diphosphonate (99mTc-MDP) hybrid single-photon emission computed tomography/computed tomography (SPECT-CT) in the diagnosis of skull base osteomyelitis (SBO) compared to planar bone scintigraphy (PBS). This was a single institution; prospective study included 23 patients with otitis externa, clinically suspected of SBO, all of them were diabetic. Three-phase bone scintigraphy and SPECT/CT were performed to all patients. The imaging modalities which had the most equivocal results were PBS (9/23) followed by SPECT (3/23). No equivocal results were detected with CT or SPECT-CT. SPECT-CT had the highest sensitivity (100%) and highest accuracy (95.7%) in diagnosis of SBO, whereas, PBS showed the lowest sensitivity (50%) and lowest accuracy (52.2%). In this study, SPECT-CT considered the best modality for accurate localization of the site of SBO involvement, followed by CT. SPECT and planar BS were less accurate in this consideration. When comparing the sensitivity of planar BS, CT, SPECT and SPECT/CT, statistical significance difference was detected between planar BS and SPECT (P = 0.057), planar BS and SPECT/CT (P = 0.001), and between CT and SPECT/CT (P = 0.031). No statistically significant difference was detected between SPECT and SPECT/CT (P = 0.250), CT and planar BS (P = 0.125), and between CT and SPECT (P = 0.508) In conclusion, 99Tc-MDP SPECT/CT has high sensitivity in the diagnosis of SBO and also provide accurate localization of the site of SBO.


  • The Effect of Anti Thyroid Medications on the Therapeutic outcome of I-131 in Hyperthyroid Patients with Graves ' disease

    by Jehan Ahmed Younis

    Objective: to detect the effect of antithyroid drugs (ATD) on the therapeutic outcome of I-131 in hyperthyroid Graves' patients. Methods: Retrospective study was done on 200 patients with Graves' disease treated with fixed dose of radioactive iodine (RAI) (12mCi). The patients were classified into three groups: Group I (n = 70) were treated by ATDs for more than 6 months and stopped it 5 days; group II (n = 70) were treated by ATDs for more than 6 months but stopped it only for two days or less, and group III (n = 60) had never been treated with ATD before RAI treatment (control group). Results: There was a statistical significant difference in the cure rate between group I and group II (P < 0.001), group II and group III (P < 0.001), but no significant difference between group I and group III (P = 0.453) three months after RAI therapy. There was a statistical significant difference in the cure rate observed between group I and the group II (P =0.002), group II and group III (P < 0.001), but no significant difference between group I and group III (P =0.060) 6 months after RAI therapy. There was a statistical significant difference between the three groups 3 (P < 0.001), and 6 months (P < 0.001), after RAI therapy.Conclusion: Administration of ATDs more than 6 month without discontinuation decreased response of RAI treatment in 3 and 6 months' follow-up. Discontinuation of ATDs for 5 days before RAI treatment is recommended.

  • Open Access

    Prevalence of subclinical peripheral vascular disease in obese Egyptian patients

    by Jehan Ahmed Younes, Nahla Dessoki El-Sayed, Ayman Ismail Kamel

    Objective: To detect subclinical peripheral vascular disease in obese Egyptian patients and establish relations between obesity, metabolic risk factors, and PVD. Methods: This was a prospective case-control study including 100 obese patients (BMI >30) (G1). In addition, 100 age and sex matched non-obese healthy subjects as a control group (G2). Both groups were subjected to duplex ultrasound, Radionuclide muscle scan. Angiography was done for 17 patients. Results: The image pattern of 99mTc-MIBI muscles uptake was studied and perfusion reserve (PR%) was calculated in (G1) and (G2). Comparison between the two groups showed statistically significant difference (P < 0.001) as regarding laboratory findings. Patients were categorized according to PR% into +ve for ischemia (mean PR% was 28.4 ± 20.3) and -ve for ischemia (mean PR% was 65.0 ± 11.4). Among (G1) 64 patients positive for ischemia by both PR% and Doppler, 36 patients were negative by Doppler and 22 of them were positive for ischemia by PR%. Angiography was done for 17 of them and proved ischemia in all of them. Conclusion: The Tc-99m sestamibi muscle scan can be used as a screening and diagnostic tool of preclinical atherosclerosis in obese patients.

  • Role and Outcome of RA131 I Therapy in Patients with Autonomous Toxic Adenoma

    by Jehan Ahmed Younis

    Radioactive iodine (RAI) therapy is preferred in the treatment of toxic autonomous adenomas because of its effectiveness, noninvasiveness, and low costs(1 ). Among patients with toxic adenomas, radioiodine therapy not only ameliorates hyperthyroidism but also reduces the size of the adenomas(2).Objective: The aim of this retrospective study is to detect the long term effects of this therapy on the thyroid function of patients with toxic adenoma treated in our department. Patients and methods: The study population included 60 cases with autonomous toxic adenoma seen at Nuclear Medicine Unit, Cairo University during the period of January 2004 till December 2010 for RAI-131 therapy. All patients were followed for 4 to 6 years (mean 5, 61 ± 0.53, median 5) following RAI- 131 therapy till December 2014. Clinical examination was done for all patients together with laboratory investigations including TSH level, FT3, FT4 measured by a radioimmunoassay (RIA).Thyroid imaging using 99m-Tc pertechnetate was done and thyroid uptake was estimated for all cases with normal reference range (0.5-4%). Neck U/S for detection of nodule size was also done. RAI dose were given us infixed dose according to nodule size (20-29 mCi).Follow up was done through clinical and laboratory evaluation guided by FT3, FT4, and TSH levels 3, 6 months after treatment then every year to exclude any possible complications. Results:131I therapeutic dose was given to all patients. The studied population was divided into two groups: Group (1): 12 patients (20%) with moderate sized nodule received 20 mCi of I- 131. Group (2): 48 patients (80%) with large sized nodule received 25-29 (mCi). No differences were observed between patients who became hypothyroid and those who became euthyroid after 131I treatment of toxic adenoma, as regards age at the time of treatment, pre 131I medical treatment, 99m-Tc pertechnetate thyroid uptake, size of the adenoma (smaller or larger than 3 cm) or pre 131I TSH levels.. Normal level of TSH is seen in 52 patients (86.7%) in their 1 st follow up visit 6 months after treatment with euthyroid state, while 8 patients (13.3%) had hypothyroidism with TSH level (>5 mIu/L) within 7.82 ±0.58 months. Among the 40 patients (66.6%) had nodules with complete suppression to the rest of thyroid tissue, no patients turned hypothyroid, whereas in the 20 patients (33.6%) who had partial suppression to the rest of thyroid tissue, 8 patients turned hypothyroid, 5 of them received 20 mCi, while the other 3 patients received 25-29 (mCi).Persistence or recurrence thyrotoxicosis was not observed in the studied population.Conclusion, Treatment of toxic adenoma with 131I in the dose of 20-29 mCi is a welltolerated therapy, leading to rapid relief of hyperthyroid symptoms. Hypothyroidism is a late side effect of RAI that needs life-long treatment and regular follow-up once or twice a year; it developed within the first year after 131I administration in 13.3% of the patients, specially those patients with partial suppression.


  • Comparison Between In vivo Gate's Method and in Vitro Plasma Sampling Method for GFR Measurement Using 99m-Tc DTPA

    by Jehan Ahmed Younis, Hosna Moustafa, Mai Hussien

    Objective: To compare between Gates GFR measurement using 99m Tc DTPA scintigraphy (in vivo method) as compared to in vitro blood sampling method (single and dual blood samples).Patients and methods: this prospective study included 40 normal individuals (group 1) and 40 patients with obstructive uropathy (group2) .The age of the group 1 ranging from: 22 to 65with mean age of 47.1±14.08 and in group 2it ranges between 27 years to 64 years with mean age of 49.12±9.1 .Group 1 included: 22 males, 18females, while group 2 included 24 males and 16 females. Both groups subjected to 99m-Tc DTPA renal scan using 8 mCi followed by blood sampling at 60 mins and 180mins post injection. Serum creatinine level was estimated for both groups and it was within normal level. Results: In group 1, the mean GFR using in vivo method was115.7 ± 29, and using in vitro method with single blood sample it was 100.1 ±16.1, and using dual blood sampling method it was 100.3±20.1.There was no significant difference between in vivo and in vitro methods (single sample and dual samples) for measuring GFR, in group 1 (p>0.05). In group 2, GFR using in vivo method was 74.1 ± 14.5, while using in vitro single sample method it was 77.5 ±24.9, and by using in vitro dual sample it was 76.8 ±24.8 with no significant difference using in vitro single sample and dual sample measurements. There is high significant correlation between in vitro single and dual sample in both groups,(r=0.90) for control group and (r=0.91) for patients group, while moderate significant correlation was found between in vivo and in vitro radionuclide single sample methods in both control and patients groups (r=0.46 and 0.57). Also moderate correlation was evident between in vivo and in vitro radionuclide dual sample methods in both groups (r=0.42 and0.68).Conclusion: No significant difference in measurement of GFR using both in vitro and in vivo methods in control group and in obstructive uropathy group ,however there is moderate correlation between in vivo and in vitro (single and dual sample) method in both groups but there is high correlation between in vitro method using single blood sample and dual blood samples.


  • Patient And Lesion-Based Analysis Of 18F-FDG PET/CT Compared With Conventional CT During Follow Up of Patients With Colorectal Carcinoma

    by Jehan Ahmed Younis

    Objective: The aim of this study was toevaluate the potential significance of 18FFDG PET/CT in detection of local ordistant disease recurrence during routinefollow up of patients with colorectal cancer(CRC) in comparison with conventionalCT. Methods: Sixty seven patients (43males and 24 females; age range 32-72years, mean 55.7±9.2 years) withhistologically proven CRC previouslytreated by surgery and chemotherapy. 18FFDG PET/CT and conventional CT wereperformed for all patients. Diagnosticability was determined on a patient and ona lesion site basis (loco-regionalrecurrence, hepatic or extra-hepaticmetastases that include LNs, bone andother sites). The final diagnosis wasobtained from the results of histopathological examination after surgery orbiopsy, or follow-up after at least 6-12months on the basis of clinico-radiologic orfollow up PET/CT. Results: On patientbasis analysis, PET/CT showed highersensitivity, specificity and accuracy thanCT in detection of local recurrence andmetastatic lesions (94.6%, 100%, and95.5% for PET/CT versus 83.9 %, 100%and 86.6% for diagnostic CT, respectively).On lesion-basis analysis, loco-regionalrecurrence was present in 23 patients,PET/CT detected all 25 lesions (100%)compared to 14/25 lesions (56%) detectedby CT. Twenty-six Liver metastatic lesionswere detected in 12 patients, PET/CT andCT accurately detected 22/26 (84.6%) and21/26 (80.7%) hepatic lesions,respectively. PET/CT identified 32/42 LNs(76%) versus 23/42 LNs (55%) identifiedby CT in 19 patients. PET/CT had higherdetectability of bone deposits than CT.PET/CT definitely changed the treatmentmodality in 28/67 patients (41.8%).PET/CT showed recurrent disease in 5/18patients with elevated carcino-embryonicantigen who had negative CT.Conclusion: 18F-FDG PET/CT provideshigh accuracy for detection of recurrent anddistant metastases than conventional CT inCRC patients during regular follow up.PET/CT changed the management strategyin a significant number of patients onlesion-based analysis. The use of 18F-FDGPET/CT in the regular follow up of CRCpatients is worth considering.

  • Role of FDG-PET/CT in Assessment of Response to Therapy in Breast Cancer Patients

    by Jehan Youniss

    Objective: We aimed to assess the roleof FDG PET/CT in evaluation of earlyresponse to chemotherapy after 2-3 cyclesand late response after 6 cycles ofchemotherapy to define responders fromnon-responders to treatment in breastcancer patients. Patients and MethodsThis prospective study included 52 femalepatients with locally advanced breastcancer, Group 1: Included 27 patientsreferred for PET/CT for assessment ofprimary lesion following 2-3 cycles ofchemotherapy, twenty patients underwent abaseline study before initiation of therapy.Group 2: Included 25 patients withrecurrent breast cancer referred for PET/CTfollowing 6 cycles of chemotherapy forassessment of disease remission. Theyunderwent a midline study after 2-3 cyclesof chemotherapy. Results Only 4patients out of 27 of group 1 showedsignificant early metabolic response withdecrease of SUV value by (65.8%)following 2-3 cycles of treatment withsignificant reduction of mean SUV maximplicating good response to therapy(p<0.005), while 23 patients showed partialmetabolic response, with reduction of meanSUV max (36.2%). Nineteen out of 25patients of group 2 (76%) showedsignificant metabolic response oncompletion of 6 cycles of chemotherapywith significant reduction of mean SUVmax (69.6%) impressive of good therapyresponse (p<0.0001), while the other 6patients (24%) showed poor metabolicresponse with mean reduction of SUV maxof 30.8% and evidences of metastaticdisease signifying poor therapy response.Conclusion: PET-CT seems to be usefulfor monitoring response to chemotherapyin locally advanced breast cancerdifferentiating responder from nonresponder in therapy evaluation.

  • Role of Radioactive Iodine-131 in Management of Hyperthyroid Patients Seen at NEMROCK: a Local Experience Study

    by Jehan Ahmed Younis

    The study aimed to assess the response of Graves Disease (GD) and Toxic MultiNodular Goiter (TMNG) to RAI-131 therapy within a follow up duration of 6 months - 3 years. Methods: 200 patients with thyrotoxicosis were evaluated at Nuclear Medicine Unit ,Cairo University during the period of January 2007 till March 2012.All patients (120 females and 80 males) were subjected to full history taking, clinical examination ,lab tests (FT3, FT4,TSH and thyroid antibodies), neck ultrasound, thyroid scan with Tc-99m pertechnetate. Thyroid gland uptake was estimated for all cases. Different doses RAI-131 therapy (12 – 29 mCi) were given to all patients with 3 years follow up guided by T3,T4 and TSH Results. The current study population included 100 patients of GD (group1) and 100 patients of TMNG (group2), Mean age in group1 was 33±9.8 while mean age in group 2 was 42±11.78 , with significant difference between age and prevalence of each type of thyrotoxicosis (P< 0.001). In group 1, 40 patients received 12 mCi of RAI-131, while 35 patients received 15 mCi. Both of them showed clinico-laboratory evidence of euothyroid state, where as the rest of this group (25 patients) received 20 mCi after which most of them developed hypothyroidism. On the other hand, group 2, it was divided into 35 patients received 20 mCi, 45 patients received 25 mCi & the remaining 20 patients received 29 mCi. The former two sub groups showed predominance of euothyroid state on follow up, while those received 29 mCi, 8 of them developed hypothyroidism. As regard number of doses, only 16 out of the 200 patients received repeated doses of RAI-131, while the rest received single dose of RAI-131. There was significant high incidence of hypothyroidism among patients received large doses of I-131 ranging 25 - 29 mCi compared to those received small doses ranging from 12 to 15 mCi, with P-value (0.05). Conclusion: RAI-131 has a very important role in treating both GD and TMNG. Different doses of RAI-131 has different impact on the thyroid gland function. Hypothyroidism is a common outcome after high dose of RAI-131 treatment.


  • Role of 18F- FDG-PET/CT in Restaging of Breast Cancer Patients with High Tumour Markers and Equivocal Radiological Imaging

    by Jehan Ahmed Younis, Hosna Moustafa, Khalid Taalab

    Objective: We aimed to assess the role of FDG PET/CT in detection of tumor recurrence in breast cancer patients with raised serum tumor markers and/or negative or equivocal abnormalities detected in other diagnostic imaging modalities. Patients and Methods: This prospective study was done on 100 previously diagnosed and treated breast cancer patients, All of patients referred for FDG-PET/CT scans in view of increased their serum tumour markers and/or equivocal abnormalities in other diagnostic imaging modalities. Clinical follow-up, tumour markers, conventional imaging modalities and FDG-PET/CT whole body scan was performed for each patient. Results: PET/CT detected recurrence and/or metastases in 63 out of 100 patients, including 23 loco-regional recurrence, 11 solitary organ involvement, 29 multiple organ involvement, whereas, other radiological modalities detected lesions in only 51 patients, those were 12 loco-regional recurrence, 24 solitary organ involvement, 15 multiple organ involvement. Fifty patients out of 59 with true positive PET/CT had raised tumor markers,either carcino-embryonic antigen (CEA) or CA 15-3 , while 2 patients with raised tumor markers showed negative PET/CT study(FN). Forty eight patients had normal serum level of tumor markers, nine of them showed positive PET/CT study. The sensitivity, specificity, positive predictive value, negative predictive value and accuracy of PET/CT were 96.7, 89.7, 93.7,94.2 and 94% respectively. These parameters were 72.1, 82, 86.3, 65.3 and 76% for conventional imaging modalities.Conclusion: PET-CT is a powerful diagnostic method in the restaging of breast cancer and detection of metastases in patients with raised serum tumor markers and/or negative or equivocal radiologic imaging modalities, however conventional imaging modalities with multiphase CT or MRI are more sensitive in detection of early small lesions in liver and lung.